| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.052 | 0.4 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.05 | 0.4 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |